

COUNTRY GENERAL INFORMATION

Total population:	51,985,780
Gender F/M (%):	50.4 / 49.6
Population, age group <15 / ≥ 15 years (%):	39 / 61
Life expectancy at birth (F/M, years):	68 / 64
GDP (PPP int \$):	4521
Income status:	Lower middle income
Administrative level, number of divisions:	2 nd sub-national administrative level, 305



EPIDEMIOLOGY

	VL	CL	PKDL
Endemicity status:	Endemic	Endemic	Endemic
Number of new cases (incidence):	1 173	0	No data
Number of relapses: ¹	25	0	N/A
Total number of cases:	1 203	398²	No data
Imported cases (#, %):	No data	0, 0%	N/A
Gender distribution (% F):	31	No data	No data
Age group distribution (% <5 / 5-14 / >14):	19 / 43 / 37	No data	No data
Incidence rate (cases/10,000 population in endemic areas):	4.36	14.26	N/A
Number of endemic 2 nd sub-national administrative level divisions:	50	4	N/A
Population at risk (% # at risk / total population): ³	5% 2703837/ 51 985780	1% 279 064/ 51 985780	N/A
Was there any outbreak?	Yes	No	N/A
Number of new foci: ⁴	No data	No data	N/A



Monthly distribution of new cases (January-December)

2020	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	66	112	109	67	158	74	60	85	84	167	134	93
CL	25	31	18	9	19	32	23	158	25	29	9	20

N/A not applicable; VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis



Number of new cases and Incidence rate/10,000 at the national level from 2005 to 2020




¹Relapse in this country is defined as: No definition available

²Type of CL cases (new or relapses) unspecified

³Defined as "Number of people living in 1st sub-national administrative level endemic areas"

⁴Defined as "In this reporting period, an area at the 1st sub-national administrative level reporting cases for the first time ever"

Disease distribution of new VL and CL cases at subnational level per 10,000 population (2020)



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Map production: WHO/UCN/NTD

CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	2012
Type of surveillance (CL / VL):	Passive
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	No data
Year latest national guidelines (CL / VL):	No data / 2017
Is leishmaniasis notifiable (mandatory report)? (CL / VL):	No data / No data
Is there a reservoir host control programme?	No data
Number of leishmaniasis health facilities (CL / VL):	4 / 43

DIAGNOSIS FOR NEW CASES

	VL	CL	PKDL
Number of people screened actively for:	No data	No data	N/A
Number of people screened passively for:	2964	398	N/A
VL cases diagnosed by RDT (% , # RDT+ / new VL cases):	74% (866/1 178)	N/A	N/A
Proportion of positive RDT (% , # RDT+ / total RDT):	No data	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides + / new cases):	2% (23/1 178)	0% (0/398)	N/A
Proportion of positive slides (% , # slides + / total slides):	52% (23/44)	0% (0/398)	N/A
Cases diagnosed clinically (% , # clinical cases / new cases):	1% (17/1 178)	100% (398/398)	N/A
Percentage of cases with HIV-VL coinfection:	No data	N/A	N/A

N/A not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? (CL / VL): No data / Yes
- ▶ Antileishmanial medicines included in the National Medicine List: Amphotericin B deoxycholate, Liposomal amphotericin B, Meglumine antimoniate, Paromomycin, Pentamidine, Sodium stibogluconate (SSG)

INITIAL TREATMENT OUTCOME FOR NEW CASES

	VL	CL
Cases that completed treatment (% , # completed treatment / new cases):	77% (908/1 178)	No data
Initial cure rate (% , # cases initially cured / new cases):	96% (1 129/1 178)	No data
Failure rate (% , # cases with treatment failure / new cases): ⁵	1% (8/1 178)	No data
Case fatality rate (% , # cases who died / new cases):	2% (21/1 178)	No data

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL = post-kala-azar dermal leishmaniasis

⁵Failure in this country is defined as: No definition available